In honor of Miles Pendleton, a CLL patient and advocate, the CLL Research Consortium and the Blood Cancer Research Fund, hosted a patient education and empowerment meeting. The meeting took place at UC San Diego Moores Cancer Center, in La Jolla, California. We will covered a wide-range of topics: from early stage CLL, prognosis, targeted therapies, to forming your own CLL team. By the end of the meeting the participants had a clear understanding of the new research developments, treatments types, and how to address needs beyond just treatment of CLL.
We are now in the process of posting videos of each of our wonderful speakers! Keep coming back to this page for the complete listing of speakers! Click on the name of the speaker and you’ll be taken to the YouTube posting!
- Dr. Thomas Kipps, CLL Research Consortium, UC San Diego
- Introduction to the CLL Research Consortium and biology of CLL
- Dr. Neil Kay, CLL Research Consortium, Mayo Clinic
- Early Stage CLL: What can I know about my prognosis and what is standard of care during early stage CLL?
- Tissue Core Overview Movie
- Overview of how the Tissue Core facilitates science.
- Dr. John Gribben, CLL Research Consortium, St. Barts Health System
- How to re-establish the immune system
- Dr. Laura Rassenti and Dr. Donna Neuberg, CLL Research Consortium Biorepository and Biostatistics Directors
- What does the tissue core do with your blood and bone marrow?
- Dr. Jeff Jones, CLL Research Consortium, The Ohio State University
- Dr. Michael Choi, CLL Research Consortium, UC San Diego
- Agnes Zsigovics, from Leukemia & Lymphoma Society
- Services and function of LLS
- Dr. Januario Castro, CLL Research Consortium, UC San Diego
- Dr. William Wierda, CLL Research Consortium, University of Texas
- Dr. Thomas Kipps, CLL Research Consortium, UC San Diego
Researchers at UC San Diego are developing a new drug to treat CLL. The drug, cirmutuzumab, is an antibody designed to attach to a protein on the surface of CLL cells. Researchers hope that this process will block cancerous cell growth and survival. Right now, cirmtuzumab is being tested for its safety and effectiveness in humans in a Phase One clinical trial. “A brand new way to target and kill blood cancer,” WNDU, features Thomas Kipps, MD, PhD.
(Source: http://www.utsandiego.com/news/2014/sep/17/ucsd-leukemia-cll-trial-kipps-cirm/, https://clinicaltrials.gov/ct2/show/NCT02222688?term=cirmtuzumab&rank=1 )
And see: http://medicalxpress.com/news/2014-10-first-in-human-trials-therapeutic-stem-cell.html
A panel discussion of “Assessing Response With Novel Agents in CLL”
Click here to see more: CLL Panel Discussion
From Patient Power:
Could a patient’s own immune system be sparked to fight chronic lymphocytic leukemia (CLL)? Research into immunotherapy—or immuno-oncology—CLL treatment approaches is currently underway and creating buzz. Dr. Thomas Kipps, a leading CLL expert, explores immuno-oncology treatments in development, how they work and why he finds the research “truly exciting.”
In honor of Miles Pendleton, CLL patient and advocate, the CLL Research Consortium, (along with the Blood Cancer Research Fund), is hosting a patient education and empowerment meeting. The meeting will take place at UC San Diego Moores Cancer Center, in La Jolla, California. We will cover a wide-range of topics: from early stage CLL, prognosis, targeted therapies, to forming your own CLL team. By the end of the meeting the participants will have a clear understanding of the new research developments, treatments types, and how to address needs beyond just treatment of CLL. Participants will also understand the importance of clinical research and how clinical research benefits everyone! For ticket or additional information go to:
Given the complexities of cancer, there is not – and likely never will be – a single way to destroy it. Instead, the oncologist’s armamentarium must be stocked with many weapons, which include diverse advances in chemotherapy, radiation, surgery and stem cell technologies. For the full story CLICK HERE!
Dr. Scott Lippman, Director of the UC San Diego Moores Cancer Center
An antibody therapy already in clinical trials to treat chronic lymphocytic leukemia (CLL) may also prove effective against ovarian cancer – and likely other cancers as well, reported researchers at the University of California, San Diego School of Medicine and the Blood Cancer Research Fund, in a study published in the Nov. 17 online early edition of the Proceedings of the National Academy of Sciences (PNAS). http://tinyurl.com/op7g28k
ASCO 2014: Dr. Kipps on ABT-199 and more on CLL (chronic lymphocytic leukemia): “Cancer is not an alien from outer space, cancer is us”
Here is a link to Dr. Koffman’s interview with Dr. Kipps: http://youtu.be/lEpN_58IcKc
An announcement earlier this month by the California Institute for Regenerative Medicine (CIRM), the state’s stem cell agency, is big news for innovative cancer treatment and the BCRF is right in the mix!
The Sanford Stem Cell Clinical Center at UC San Diego Health System, which is led by Lawrence Goldstein, PhD, and Catriona Jamieson, MD, PhD, was named one of three new “alpha clinics” by CIRM. Dr. Jamieson is the principal investigator on the alpha grant and co-leader of the Moores Cancer Center Hematologic Malignancies program. This designation comes with an $8 million award which will help provide vital infrastructure for establishing a comprehensive regenerative medicine clinical hub for first-in-human stem cell-related clinical trials including cancer treatment.
Recently, the Sanford Center launched three such trials including a Phase I trial to assess the safety and efficacy of a new monoclonal antibody for patients with chronic lymphocytic leukemia (CLL). The drug, called cirmtuzumab,was developed at Moores Cancer Center in the laboratory of Thomas Kipps, MD, PhD, co-leader of the Moores Cancer Center Hematologic Malignancies program.